Rachel Klemovitch, Assistant Editor04.11.24
Getinge, recently achieved an EU MDR certificate for its Advanta V12, that now aligns the indication to Aortoiliac Occlusive Disease (AIOD). The certification highlights Getinge’s dedication to providing safe, effective, high-quality products, and its ongoing commitment to regulatory standards.
The Advanta V12 covered stent system is known for its versatility, precision, and predictability. It is the only durable solution backed by decades of clinical and real-world evidence and has met the needs of surgeons and patients for over 20 years.
Chad Carlton, VP of Vascular Systems at Getinge commented: “Receiving the new EU MDR certification is a proud moment for Getinge. It is a clear reflection of our strategic vision, accompanied by the hard work and persistence of our team. This investment in regulatory excellence not only supports our growth ambitions and future endeavors but also reinforces our commitment in making a positive impact on the lives of the patients we serve.”
When aortoiliac occlusive disease involves the aortic bifurcation or proximal common iliac arteries, a kissing stent configuration is recommended. The Advanta V12 covered stent system is indicated for treating patients diagnosed with renal artery stenosis and/or aortoiliac occlusive disease, including lesions at the aortic bifurcation, when endovascular therapy is required.
The Advanta V12 covered stent system is known for its versatility, precision, and predictability. It is the only durable solution backed by decades of clinical and real-world evidence and has met the needs of surgeons and patients for over 20 years.
Chad Carlton, VP of Vascular Systems at Getinge commented: “Receiving the new EU MDR certification is a proud moment for Getinge. It is a clear reflection of our strategic vision, accompanied by the hard work and persistence of our team. This investment in regulatory excellence not only supports our growth ambitions and future endeavors but also reinforces our commitment in making a positive impact on the lives of the patients we serve.”
When aortoiliac occlusive disease involves the aortic bifurcation or proximal common iliac arteries, a kissing stent configuration is recommended. The Advanta V12 covered stent system is indicated for treating patients diagnosed with renal artery stenosis and/or aortoiliac occlusive disease, including lesions at the aortic bifurcation, when endovascular therapy is required.